Ivax/Nycomed merger would create contrast media, generic drug firm with $2.5 bil. in sales.
This article was originally published in The Gray Sheet
Executive Summary
IVAX IV BUSINESS TO BENEFIT FROM NYCOMED'S U.S. HOSPITAL TIES as a result of the proposed $6.5 bil. merger of the two firms, the companies say. The deal would enable Ivax' intravenous solutions and products business to "benefit substantially" from the "excellent U.S. hospital relationships" and "international hospital distribution channels" Hafslund Nycomed has established through its market-leading position in contrast imaging agents. Miami-based Ivax and Oslo, Norway-based Hafslund Nycomed announced Oct. 18 a definitive agreement to combine their health care products businesses.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.